Monell Center Study Identifies GLP-1 Therapies as a Possible Treatment for Rare Genetic Disorder Bardet-Biedl Syndrome
Monell Center investigators identified that GLP-1R agonists, a class of drugs currently used to treat type-2 diabetes and obesity, as a promising therapeutic for managing the metabolic complications associated with Bardet-Biedl Syndrome (BBS), a...
17-Apr-2025 8:45 PM EDT
Add to Favorites